论文部分内容阅读
目的:比较门冬胰岛素30(BIAsp30)与甘精胰岛素(IG)联合瑞格列奈治疗老年初发2型糖尿病患者的临床疗效及安全性。方法:选取河北医科大学第一医院2016年7月至2019年7月诊治的新诊断老年2型糖尿病患者60例为研究对象，采用随机数字表法分为A组、B组各30例。A组患者给予BIAsp30治疗，B组患者给予IG联合瑞格列奈片治疗，两组疗程均为2周。于治疗后1周、2周测体质量指数、空腹及餐后2 h血糖、糖化血红蛋白、1，5-脱水葡萄糖醇(1，5-AG)，治疗前及治疗后2周复查空腹及2 h C肽，比较不同治疗方案血糖达标时间、胰岛素用量、低血糖发生次数及胰岛功能恢复情况。结果:两组治疗后1周及2周空腹及餐后2 h血糖均较治疗前明显下降，且治疗1周时A组血糖下降较B组明显，差异有统计学意义(空腹n t＝2.58，n P<0.05；餐后2 h血糖n t＝2.46，n P0.05)；1，5-AG于治疗1周及2周均明显升高，1周时A组[(127.08±20.28)μmol/L]升高较B组[(100.65±21.34)μmol/L]明显，差异有统计学意义(n t＝8.93，n P<0.05)；治疗2周空腹及餐后2 h C肽水平较治疗前增加，空腹两组分别为(2.29±0.45)μIU/mL、(2.48±0.26)μIU/mL(n t＝3.72、3.45，均n P<0.05)，餐后2 h两组分别为(4.95±082)μIU/mL、(5.03±0.14)μIU/mL，差异均有统计学意义(n t＝4.14、3.54，均n P<0.05)。A组患者血糖达标时间为(10.35±4.10)d，短于B组的(12.38±4.22)d，差异有统计学意义(n t＝8.32，n P<0.05)；A组患者达标时所需胰岛素量为(45.14±8.42)U·kgn －1·dn －1，多于B组的(24.88±7.36)U·kgn －1·dn －1，差异有统计学意义(n t＝9.06，n P<0.01)。n 结论:BIAsp30与IG联合瑞格列奈均可有效降低老年初发2型糖尿病患者的空腹及餐后2 h血糖，且IG低血糖发生事件较BIAsp30轻，但血糖达标时间长于BIAsp30，通过监测1，5-AG可以作为参照及时调整降糖方案。“,”Objective:To compare the efficacy and safety between biphasic insulin aspart 30 injection and insulin glargine combined with repaglinide in the newly diagnosed type 2 diabetes in the elderly patients.Methods:A total of 60 elderly patients with type 2 diabetes who were newly diagnosed in the First Hospital Affiliated to Hebei Medical University were selected as study objects, and they were divided into group A and group B according to the random digital table method, with 30 cases in each group.Group A was treated with aspart 30 injection, and group B was treated with glargine combined with repaglinide tablets for 2 weeks.The BMI, FPG, 2hPG, HbA1c, 1, 5-AG were detected after treatment for 1 and 2 weeks, and the FCP, PCP were detected before and after treatment.Results:The FPG and 2hPG of the two groups decreased significantly after treatment for 1 week and 2 weeks, and the blood glucose of group A decreased significantly after 1 week of treatment compared with group B, and the difference was statistically significant(FPGn t=2.58, 2hPGn t=2.46, all n P<0.05).1, 5-AG increased significantly at 1 week and 2 weeks after treatment.At 1 weekafter treatment, the increase was more significant in group A than group B, and the difference was statistically significant(n t=8.93, n P<0.05). After 2 weeks of treatment, the levels of FCP and 2hCP of both two groups were increased compared with before treatment, and the differences were statistically significant(FCPn t=3.72, 3.45, 2hCPn t=4.14, 3.54, all n P<0.05). The time of blood glucose reaching the standard in group A was(10.35±4.10)d, which was shorter than that in group B [(12.38±4.22)d], and the difference was statistically significant(n t=8.32, n P<0.05). The dosage of insulin required by the patients in group A was(45.14±8.42) U·kgn -1·dn -1, which was higher than that in group B [(24.88±7.36)U·kgn -1·dn -1], and the difference was statistically significant(n t=9.06, n P<0.01).n Conclusion:Both BIAsp30 and IG combined with repaglinide can effectively reduce FPG and 2hPG of patients with type 2 diabetes newly diagnosed in the elderly.Besides, the occurrence of hypoglycemia in the glargine group is lighter than that in the BIAsp30 group, and the time of blood glucose reaching the standard is longer than that in the aspart 30 injection group.Monitoring 1, 5-AG can be used as a reference for timely adjustment of hypoglycemia programs.